Core Viewpoint - Company Basilea Pharmaceutica has announced that its pipeline candidate CS2015 has been selected for presentation at the 2025 ACAAI Annual Scientific Meeting, highlighting its potential in treating type 2 inflammatory diseases [1] Group 1: Product Development - CS2015 is a dual-specific antibody targeting both OX40L and TSLP, representing a potential first-in-class or best-in-class therapy [1] - The drug aims to provide new treatment strategies for atopic dermatitis (AD), asthma, and chronic obstructive pulmonary disease (COPD) by dual inhibition of key regulatory factors in Th2-mediated inflammatory responses [1] Group 2: Event Participation - The ACAAI Annual Scientific Meeting will take place from November 6 to 10 in Orlando, USA, where CS2015 will be showcased through an electronic poster presentation and live oral presentation [1]
基石药业-B(02616)将携CS2015(OX40L/TSLP双特异性抗体)亮相ACAAI 2025